Pfizer succeeds in late-stage trial for colorectal cancer therapy

Pfizer (NYSE:PFE) announced Saturday that its colorectal cancer therapy Braftovi, as part of a combination regimen, reduced tumor size (confirmed objective response rate) in a late-stage trial with a clinically meaningful and statistically significant effect.

Following a data readout from